Plus Therapeutics Regains Nasdaq Compliance, Resolving Delisting Risk
PSTV has more than doubled off its 52-week low of $2.9.
Summary
Plus Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, effectively resolving a prior delisting risk following a recent reverse stock split.
Key Events · Corporate Governance and Compliance · PSTV
-
Nasdaq Compliance Regained
Plus Therapeutics, Inc. received written notice from The Nasdaq Stock Market LLC confirming it has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
-
Delisting Risk Resolved
This notification resolves the previously disclosed Nasdaq delisting risk, which was a significant concern for the company's continued listing.
-
Follows Reverse Stock Split
Compliance was achieved after a one-for-twenty-five reverse stock split, which became effective on April 2, 2026.
Analysis · PSTV · Industrial Applications And Services
This filing is highly important as it confirms Plus Therapeutics has successfully resolved the Nasdaq minimum bid price deficiency, a significant risk previously highlighted in the company's 10-K. Regaining compliance removes a major overhang and potential delisting threat, which is crucial for maintaining investor confidence and market liquidity. While the compliance was achieved through a reverse stock split, the successful outcome of retaining the Nasdaq listing is a positive development for the company's operational stability and access to capital markets.
At the time of this filing, PSTV was trading at $7.56 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $50.1M. The 52-week trading range was $2.90 to $30.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.